Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Slightly Bullish +15

Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers

Company update Drug approval AI-generated analysis

📉 BMY stock closed at US$63.88, trading below a DCF model's intrinsic value estimate which implies a discount to future cash generation.

💰 The company produced roughly $11.5 billion in free cash flow over the last twelve months with a forecasted mature profile.

🤝 A bullish narrative rates BMY as 22% undervalued, highlighting the BioNTech partnership for industry leadership in immuno-oncology.

⚠️ A bearish narrative rates BMY as 30% overvalued due to severe revenue cliffs expected after 2026 from patent expirations on Eliquis, Opdivo, and Revlimid.

🧬 Recent positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS strengthens the outlook for oncology cash flows.

📈 BMY delivered a 51.6% gain over the past year driven by fresh drug data and an expanding pipeline.

Bullish Signals
  • The company generated approximately $11.5 billion in free cash flow over the last twelve months, demonstrating strong underlying cash generation.
  • Positive Phase 3 EXCALIBER-RRMM data for ZENBEXUS has strengthened the case for ongoing oncology cash flows and revenue mix shifts.
  • A breakthrough partnership with BioNTech positions BMY's pipeline for industry leadership in immuno-oncology and radiopharmaceuticals.
Risk Factors
  • Analysts note that the current share price implies a clear discount to future cash generation, suggesting caution among investors.
Full Analysis
Bristol-Myers Squibb (BMY) shares recently closed at US$63.88, trading below a Discounted Cash Flow (DCF) model's estimated intrinsic value. The company generated approximately $11.5 billion in free cash flow over the last twelve months, with forecasts projecting a mature profile featuring an initial step-up followed by a decline over the next decade. Analysts at Simply Wall St present diverging narratives regarding the stock's valuation. A bullish case suggests BMY is 22% undervalued, citing breakthrough partnerships like the BioNTech deal that position the company for leadership in immuno-oncology and radiopharmaceuticals. Conversely, a bearish view argues the stock is 30% overvalued due to impending revenue cliffs associated with the loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026. Recent clinical progress continues to influence investor sentiment regarding BMY's future cash flows. Positive Phase 3 data for ZENBEXUS in multiple myeloma has strengthened the case for ongoing oncology revenue, while broader efforts in immunology are expected to shift the company's revenue mix and investment needs over time.